GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advanced Accelerator Applications SA (NAS:AAAP) » Definitions » Short Interest

Advanced Accelerator Applications (Advanced Accelerator Applications) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Advanced Accelerator Applications Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.


Competitive Comparison of Advanced Accelerator Applications's Short Interest

For the Biotechnology subindustry, Advanced Accelerator Applications's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced Accelerator Applications's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advanced Accelerator Applications's Short Interest distribution charts can be found below:

* The bar in red indicates where Advanced Accelerator Applications's Short Interest falls into.



Advanced Accelerator Applications (Advanced Accelerator Applications) Business Description

Traded in Other Exchanges
N/A
Address
Advanced Accelerator Applications SA is a French-based radiopharmaceutical company. It develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products. The molecular nuclear medicine is a medical specialty that uses trace amounts of radioactive compounds to create functional images of organs and lesions and to treat diseases including cancer. The company includes a portfolio of six diagnostic positron emission tomography (PET) and single-photon emission computed tomography (SPECT) products. Its PET and SPECT are imaging techniques in molecular nuclear diagnostics with applications in clinical oncology, cardiology and neurology. Its other diagnostic product is Gluscan, its branded fluorodeoxyglucose PET imaging agent.

Advanced Accelerator Applications (Advanced Accelerator Applications) Headlines